A Randomized Trial Comparing the ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent for Treatment of Superficial Femoral and/or Proximal Popliteal Arteries

Trial Profile

A Randomized Trial Comparing the ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent for Treatment of Superficial Femoral and/or Proximal Popliteal Arteries

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Arterial occlusive disorders; Vascular restenosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IMPERIAL
  • Sponsors Boston Scientific Corporation
  • Most Recent Events

    • 03 Dec 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Dec 2017.
    • 25 Oct 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Nov 2018.
    • 21 Feb 2017 Planned End Date changed from 1 Jan 2022 to 1 Mar 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top